Status:
UNKNOWN
Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With Asthma
Lead Sponsor:
Medical University of Lodz
Conditions:
Asthma
Eligibility:
All Genders
6-17 years
Phase:
PHASE2
Brief Summary
Exhaled breath condensate (EBC) has emerged as a novel noninvasive technique for assessment of airway inflammation, and it provides information on airway lining fluid composition. Traditionally, such ...
Detailed Description
Markers that can be identified in the EBC of patients with asthma include pH, hydrogen peroxide, nitrogen oxides, eicosanoids, isoprostanes, adenosine, certain cytokines, chemokines, and growth factor...
Eligibility Criteria
Inclusion
- children with mild to moderate asthma allergic to house dust mite exposed/nonexposed to tobacco smoke
- healthy children
Exclusion
- sensitization to allergens other than house dust mites
- other chronic diseases
- asthma exacerbation
- pregnancy
- oral corticosteroids for 4 weeks before the study
- montelukast sodium for 2 weeks before the study
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2014
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00961155
Start Date
August 1 2009
End Date
June 1 2014
Last Update
December 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pediatrics and Allergy, Medical University of Lodz, Poland
Lodz, Łódź Voivodeship, Poland